New 8-hydroxyquinoline derivatives as promising therapeutic approaches targeting neurodegeneration
DOI:
https://doi.org/10.48797/sl.2023.92Keywords:
PosterAbstract
Background: Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis are recognized as the most prevalent neurodegenerative diseases (NDs), presenting a huge burden for society. These diseases share common pathophysiological mechanisms, such oxidative stress, dysfunction in iron metabolism, ferroptosis, and protein misfolding [1-4]. Given their powerful metal chelating and antioxidant properties, 8-hydroxyquinoline (8-HQs) derivatives have emerged as attractive therapeutic approaches for the development of innovative therapies for NDs [5]. Objective: To assess, in vitro, the neuroprotective effects of 12 newly synthesized 8-HQs with iron chelation and radical scavenging capacity, using differentiated neuronal SH-SY5Y cells as an in vitro model. Methods: The cytotoxicity of 8-HQs was initially evaluated using the MTT reduction and neutral red uptake assays, 24 hours after exposure, to select non-cytotoxic concentrations. The neuroprotective effects of the 8-HQs against the cytotoxicity induced by iron (III), erastin (a ferroptosis inducer), or by the combination of the two aggressors, were then evaluated. Their capacity to decrease tert-butyl hydroperoxide (t-BHP)-induced cytotoxicity was also investigated, aiming to elucidate the potential of the novel 8-HQs derivatives to counteract oxidative stress. The most promising 8-HQs were also tested for their ability to protect against the neurotoxin 1-methyl-4-phenylpyridinium (MPP+), which is frequently used to mimic Parkinson's disease in in vitro models [6]. Results: Some of the 8-HQs significantly protected SH-SY5Y cells against the cytotoxicity induced by iron (III), erastin, or by the combined effects iron (III) + erastin. Moreover, several 8-HQs also remarkably reduced the cytotoxic effects induced by both t-BHP and MPP+. Conclusions: The 8-HQs showed outstanding neuroprotective properties against the harmful effects induced by distinct chemical aggressors, highlighting their potential to become effective disease-modifying agents for counteracting neurodegeneration.
References
1. Checkoway, H.; Lundin, J.I.; Kelada, S.N.; Neurodegenerative diseases. IARC Sci Publ 2011, 407-419.
2. Lane, C.A.; Hardy, J.; Schott, J.M. Alzheimer's disease. Eur J Neurol 2018, 25, 59-70.
3. Kalia, L.V.; Lang, A. E. Parkinson's disease. Lancet 2015, 386, 896-912.
4. Feldman, E.L.; Goutman, S. A.; Petri, S.; Mazzini, L.; Savelieff, M.G.; Shaw, P.J.; et al. Amyotrophic lateral sclerosis. Lancet, 2022, 400, 1363-80.
5. Lim, C.K.; Kalinowski, D.S.; Richardson, D.R. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Mol Pharmacol 2008, 74, 225-235.
6. Xicoy, H.; Wieringa, B.; Martens, G.J.M. The SH-SY5Y cell line in Parkinson’s disease research: a systematic review. Mol Neurodegener 2017, 12, 10
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 R. Marques-Oliveira , A. R. Alfenim, P. Soares , F. Borges , F. Remião, C. Fernandes, R. Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.